|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Speedel Holding AG Reports on Data Published at Hypertension 2008 Medical Congress
6/19/2008 2:40:09 PM
BASEL, SWITZERLAND and BRDGEWATER, NJ--(Marketwire - June 19, 2008) - Speedel Holding Ltd. (SWX: SPPN) today announced that data for two of its developmental product candidates were presented at Hypertension 2008, the joint meeting of the International Society of Hypertension (ISH) and the European Society of Hypertension (ESH) in Berlin (14- 19 June 2008). Results from the Phase IIa proof-of-concept trial with SPP635, one of the company's next generation of renin inhibitors, demonstrated strong efficacy and good safety[2],[3]. Based on these results Speedel continues Phase IIa development in a special population of diabetic patients with mild-to-moderate hypertension. For SPP301, an endothelin receptor A antagonist in development for patients with diabetes, results of several pre-clinical investigations were presented[4],[5],[6].
|
|
|
|
|
|
|
|
|
|
|